CAR T cells produced in vivo to treat cardiac injury

🤖 Plain-English Summary

Fibrosis affects millions of people with cardiac disease. Treatment with modified mRNA-targeted LNPs reduced fibrosis and restored cardiac function after injury.

🔑 Key Findings

• We developed a therapeutic approach to generate transient antifibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modified messenger RNA (mRNA) in T cell–targeted lipid nanoparticles (LNPs).
• The efficacy of these in vivo–reprogrammed CAR T cells was evaluated by injecting CD5-targeted LNPs into a mouse model of heart failure.
• Efficient delivery of modified mRNA encoding the CAR to T lymphocytes was observed, which produced transient, effective CAR T cells in vivo.

🔗 Related Resources